Acasti Q2 FY2024 net loss falls to $3.3M; first patient dosed in pivotal GTX-104 trial

Grace Therapeutics, Inc.

2024-Q2 EPS reported -$0.97

Net loss of $3.3M ($0.43/share) vs $5.0M ($0.66/share) in Q2 FY2023; R&D spending cut to $0.4M.
Cash and cash equivalents $27.0M at Sep 30, 2023, down $0.9M from Mar 31, 2023; $7.5M private placement closed in Sep 2023.
First patient enrolled in STRIVE-ON Phase 3 trial of GTX-104 for aneurysmal subarachnoid hemorrhage (aSAH).
GTX-104 NDA submission to FDA on track for first half of 2025.
Private placement led by ADAR1 Partners; proceeds to fund Phase 3 trial, NDA prep, and working capital.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Grace Therapeutics, Inc. reported three months ended September 30, 2023 results: net income Net loss $3.3 million or $0.43 per share, EPS $0.43 per share.

Period: three months ended September 30, 2023
Net income: Net loss $3.3 million or $0.43 per share
EPS: $0.43 per share
Result: reported results

Exact text from the filing

Net loss $3.3 million or $0.43 per share for the three months ended September 30, 2023 decreased by $1.7 million from the net loss of $5.0 million or $0.66 per share for the three months ended September 30, 2022.

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

Grace Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-062474

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.